The effect of a hepatitis pay-for-performance program on outcomes of patients undergoing antiviral therapy

Eur J Public Health. 2017 Dec 1;27(6):955-960. doi: 10.1093/eurpub/ckx114.

Abstract

Background: To examine the effect of a participatory pay-for-performance (P4P) program in Taiwan on health outcomes for patients with severe hepatitis B or C.

Methods: This study adopted 4-year panel data from the databases of the National Health Insurance Administration (NHIA) in Taiwan. Using the caliper matching method to match patients in the P4P (experimental) group with those in the potential comparison group on a one-to-one basis for the year 2010, we tracked patients up to the year 2013 and employed Cox proportional-hazards regression models to evaluate the effect on patient outcomes.

Results: The P4P group did not have a lower risk (HR = 0.44, P = 0.05) of hospital admission for severe hepatitis patients (i.e. need antiviral therapy). The risk of developing liver cirrhosis was also lower, but the reduction was not statistically significant (HR = 0.92, P = 0.77).

Conclusions: This study found that participatory-type P4P has not resulted in reduced hospital admission of hepatitis B or C patients who need antiviral therapy. The means by which the participatory P4P program could strengthen patient-centered care to achieve better patient health outcomes is discussed in detail.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antiviral Agents / therapeutic use*
  • Case-Control Studies
  • Female
  • Hepatitis B / complications
  • Hepatitis B / drug therapy*
  • Hepatitis C / complications
  • Hepatitis C / drug therapy*
  • Hospitalization / statistics & numerical data
  • Humans
  • Male
  • Middle Aged
  • Reimbursement, Incentive* / organization & administration
  • Taiwan
  • Treatment Outcome

Substances

  • Antiviral Agents